DW-1030
Phase 3Small molecule
Daewon Pharmaceutical Co., Ltd.DW-1030 is one of 43 small molecule programs targeting Back pain. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
87 competitors in Back Pain
#DrugCompanyPhaseTrials
1Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Vivarin
HHikma Pharmaceuticals LLC
Approved
Buprenorphine/naloxone
AstellasApproved
Celebrex
PPhiladelphia Eye Associates
Approved
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Suboxone
IIndivior Inc.
Phase 3
Aspercreme Warming
AAveritas Pharma, Inc.
Phase 3
Botox
AbbViePhase 3
Standard Medical Care
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
Buprenorphine IV
PPurdue Pharma LP
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DW-1030. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details